logo
Overview
Discover
Watchlists
Portfolios
Heatmap
Sectors
Trendscore
Performers
Alerts
Options
Earnings
Screeners
Scanners
Backtests
Strategies
Comparisons
Charts
Sign in
Discover
BYSI
BeyondSpring Inc.
1.23
4 x 1.18
11 x 1.20
bid
ask
-
0.02
1.60%
11:56 AM
timesize
Ytd-24.54%
1y-34.22%
1.23
day range
1.26
1.16
52 week range
2.44
Open1.26Prev Close1.25Low1.23High1.26Mkt Cap51.40M
Vol29.07KAvg Vol23.01KEPS-0.19P/E-6.49Forward P/E-3.72
Beta0.43Short Ratio83.51Inst. Own13.80%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-1250-d Avg1.57200-d Avg1.681yr Est1.25

BYSI News

benzinga.com
BeyondSpring Appoints Min Qiu As CEO, Effective July 1

Dr. Lan Huang, PhD, remains Chairman of BeyondSpring, committing her time to SEED Therapeutics, wher

BeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value
globenewswire.com
BeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN

FLORHAM PARK, N.J., June 04, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSprin
benzinga.com
Beyondspring Announces Updated Efficacy And Safety Data From Its Phase 2 303 Study Evaluating Pembro

Meaningful clinical benefit: Median PFS at 7.0 months, median DoR is 9.3 months with DCR of 79.5% in

BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026
globenewswire.com
BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of

Meaningful clinical benefit: Median PFS at 7. 0 months, median DoR is 9. 3 months with DCR of 79. 5%

BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting
globenewswire.com
BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting

FLORHAM PARK, N.J., May 18, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com
BeyondSpring Q1 EPS $(0.05) Up From $(0.06) YoY

BeyondSpring (NASDAQ:BYSI) reported quarterly losses of $(0.05) per share. This is a 16.67 percent i

BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com
BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update

AACR 2026 Data Positions Plinabulin as a Potential Backbone Agent to Combine with Antibody-Drug Conj

BeyondSpring Reports Compelling New Data: Plinabulin Advances Both the Anticancer Efficacy and Safety of ADC Drugs
globenewswire.com
BeyondSpring Reports Compelling New Data: Plinabulin Advances Both the Anticancer Efficacy and Safet

New Preclinical Results at AACR 2026 Show Plinabulin Dramatically Improves Complete Response Rates a

BeyondSpring (NASDAQ:BYSI) Stock Passes Above 50 Day Moving Average – Here’s Why
defenseworld.net
BeyondSpring (NASDAQ:BYSI) Stock Passes Above 50 Day Moving Average – Here’s Why

BeyondSpring Inc. (NASDAQ: BYSI - Get Free Report) passed above its fifty day moving average during

BeyondSpring Files 2025 Annual Report on Form 10-K
globenewswire.com
BeyondSpring Files 2025 Annual Report on Form 10-K

FLORHAM PARK, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpri

12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session

BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Conference
globenewswire.com
BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Conference

FLORHAM PARK, N.J., Feb. 09, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a clinical-s

12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session

Financial Contrast: Lisata Therapeutics (NASDAQ:LSTA) vs. BeyondSpring (NASDAQ:BYSI)
defenseworld.net
Financial Contrast: Lisata Therapeutics (NASDAQ:LSTA) vs. BeyondSpring (NASDAQ:BYSI)

BeyondSpring (NASDAQ: BYSI - Get Free Report) and Lisata Therapeutics (NASDAQ: LSTA - Get Free Repor

Critical Review: Cyclerion Therapeutics (NASDAQ:CYCN) & BeyondSpring (NASDAQ:BYSI)
defenseworld.net
Critical Review: Cyclerion Therapeutics (NASDAQ:CYCN) & BeyondSpring (NASDAQ:BYSI)

BeyondSpring (NASDAQ: BYSI - Get Free Report) and Cyclerion Therapeutics (NASDAQ: CYCN - Get Free Re

Why ZIM Integrated Shipping Services Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
benzinga.com
Why ZIM Integrated Shipping Services Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Movi

12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session

Why MindWalk Holdings Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
benzinga.com
Why MindWalk Holdings Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket

BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path
globenewswire.com
BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large

FLORHAM PARK, N.J., Dec. 12, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a clinical-s

12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session

BeyondSpring Inc. (BYSI) 2025 Annual Shareholders Meeting (Transcript)
seekingalpha.com
BeyondSpring Inc. (BYSI) 2025 Annual Shareholders Meeting (Transcript)

BeyondSpring Inc. (NASDAQ:BYSI ) 2025 Annual Shareholders Meeting Call September 15, 2025 9:00 AM ED

BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure
globenewswire.com
BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic

FLORHAM PARK, N.J., July 07, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) today announc

BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting
globenewswire.com
BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Doc

FLORHAM PARK, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSprin

BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update
globenewswire.com
BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update

FLORHAM PARK, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a clinical‑st

BeyondSpring Files 2024 Annual Report on Form 10-K
globenewswire.com
BeyondSpring Files 2024 Annual Report on Form 10-K

FLORHAM PARK, N.J., March 27, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpri

SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors
globenewswire.com
SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39

KING OF PRUSSIA, Pa., Jan. 28, 2025 (GLOBE NEWSWIRE) -- SEED Therapeutics Inc. (“SEED”), a biotechno

BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies
globenewswire.com
BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Ad

FLORHAM PARK, N.J., Jan. 28, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSprin

BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting
globenewswire.com
BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembro

In 30 metastatic NSCLC patients who progressed on PD-1/PD-L1 inhibitors, the triple IO combo regimen
benzinga.com
Why SOPHiA GENETICS Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday's Mid-D

Shares of SOPHiA GENETICS SA (NASDAQ: SOPH) fell sharply during Tuesday’s session after the company
benzinga.com
Why Avaya Holdings Shares Are Trading Lower By 62%? Here Are 62 Stocks Moving In Friday's Mid-Day Se

Gainers Allarity Therapeutics, Inc. (NASDAQ: ALLR) gained 240% to $0.90. Allarity Therapeutics, l
benzinga.com
Stocks That Hit 52-Week Lows On Tuesday

  On Tuesday, 838 companies hit new 52-week lows.
benzinga.com
Stocks That Hit 52-Week Lows On Wednesday

  On Wednesday, 807 companies reached new 52-week lows.
benzinga.com
Stocks That Hit 52-Week Lows On Thursday

  During Thursday, 849 stocks hit new 52-week lows.
benzinga.com
Stocks That Hit 52-Week Lows On Tuesday

    Tuesday's session saw 729 companies set new 52-week lows.
benzinga.com
Stocks That Hit 52-Week Lows On Thursday

Stocks That Hit 52-Week Lows On Thursday
benzinga.com
Stocks Which Set New 52-Week Low Yesterday, October 23rd

Stocks Which Set New 52-Week Low Yesterday, October 23rd